Internationally trained medical team
Records-first medical review
19+ years of stem cell research
Clinically Enhanced UC-MSC+ Therapies
The Regeneration Center coordinates records review, physician consultation and regenerative-medicine services in Bangkok. A consultation considers the diagnosis, current care, imaging, laboratory findings and the evidence for the actual cell preparation. Eligibility, possible benefit and treatment risks require an individual assessment.
Read the center’s full clinical background
The center has operated since 2007. Its care pathway brings together clinical facilities, laboratory preparation and follow-up.
Cell sources and preparations differ. Peripheral-blood progenitor cells, bone-marrow preparations, cord-blood cells and mesenchymal stromal cells are not interchangeable treatments. Radiology, genetic testing, immune evaluation and cell banking may form part of a proposed care pathway when relevant to the individual case.
Hematopoietic stem-cell transplantation has established uses in selected blood and immune disorders. That evidence cannot be transferred automatically to other cell preparations or to proposed repair of the heart, lungs, kidneys or nervous system. Review the intervention, the studied population, meaningful outcomes and adverse events separately.
Enhanced UC-MSC+ Stem Cell Therapies
Cellular-therapy evaluation brings together the diagnosis, medical history, current treatment, imaging, laboratory findings and the evidence relevant to the requested condition. That review helps the medical team decide whether a consultation is appropriate and which questions must be resolved before a protocol can be considered.
Explore regenerative medicineA long-standing regenerative-medicine program
Since 2007, the center has coordinated regenerative-medicine inquiries through a Bangkok network of clinical facilities and laboratory services. The care pathway connects records review, physician consultation, diagnostics, cell preparation and follow-up while keeping every decision tied to the individual case.
Meet the centerFunctional medicine around the cellular protocol
Autologous and allogeneic cell sources are not interchangeable products. Source selection, laboratory preparation, route and supporting care depend on the clinical question, health status and available evidence. Functional-medicine review, radiology, genetic testing, immune evaluation and cell banking can be incorporated when they add useful clinical context.
Explore functional medicineEstablished foundations, careful translation
The long clinical history of hematopoietic stem-cell transplantation sits alongside newer, still-evolving applications of cellular medicine. Our role is to separate established practice from investigational use, review the evidence for the specific diagnosis and explain uncertainty, alternatives and eligibility in language patients and families can use.
Review clinical evidenceAdvanced Medicine. Compassionate Care.
Explore the care spaces patients use during consultation, treatment and follow-up in Bangkok.
Focused programs for complex and degenerative conditions
Explore four frequently requested pathways. Each opens into condition-specific information and begins with medical-record review rather than a preset treatment package.
Digestive and liver conditions include different diseases with different treatment needs. Information about liver disease, Type 1 diabetes, Type 2 diabetes, diabetic nephropathy, pancreatitis, and Crohn's disease or ulcerative colitis should be read in that diagnosis-specific context. The presence of stem cells in a tissue does not show that an infused mesenchymal preparation reverses disease. Assessment should identify the actual product, clinical evidence and appropriate standard care.
Kidney stem cell therapy is being investigated for renal conditions. Changes in inflammatory signaling, including the paracrine effect, do not by themselves establish replacement of kidney tissue, restored filtration or an alternative to dialysis or transplantation. Evidence for one kidney diagnosis does not establish benefit in polycystic kidney disease or another disorder. Review eligibility, kidney-function measurements, follow-up and risks alongside existing renal care.
Orthopedic assessment distinguishes knee injuries, arthritic hips, shoulder injuries, sports injuries, cartilage, ligament and tendon injuries, degenerative disc disease, and osteoarthritis. Cell-based procedures differ in preparation, route and evidence. A proposed repair mechanism does not establish restored cartilage, elimination of pain or avoidance of otherwise indicated surgery. Diagnosis, rehabilitation and comparison with appropriate nonsurgical and surgical care remain central to a treatment decision.
Regenerative medicine and age-management therapies involve different proposed interventions and outcomes. The properties of multipotent stem cells do not establish longer life, improved vitality or visible rejuvenation within one or two weeks. Evidence about breast reconstruction does not demonstrate a general anti-aging benefit. Discuss the intended outcome, supporting human evidence, procedural risks, alternatives and follow-up before deciding on a program.
Request Medical Evaluation
Personalized care begins with a confidential review of your medical history.
Request evaluationWhere clinical excellence meets excellent results A better healthcare experienceTwo cell-source pathways, selected for the individual case
Autologous and allogeneic describe where the cells come from. They do not describe a condition, outcome or one-size-fits-all treatment.
Autologous protocols
Cells are collected from the patient, prepared for the intended clinical pathway and returned under physician supervision. Collection method, cell yield and suitability depend on health status and the treatment objective.
More about this pathway
Autologous preparation can involve peripheral-blood progenitor cells, bone-marrow-derived cells or adipose-derived cells. Before collection, the team reviews current medication, infection risk, blood counts, anesthesia or procedure considerations and whether the patient’s own cells are appropriate for the intended application.
- Peripheral blood PBSC
- Bone marrow BMSC
- Adipose-derived cells
Allogeneic UC-MSC+ protocols
Cells are derived from screened donor tissue and expanded or prepared through a controlled laboratory pathway. Source selection depends on the condition, available evidence, quality controls and physician review.
More about this pathway
Donor-derived preparations may originate from umbilical-cord tissue, Wharton’s jelly, placental tissue, dental pulp or other screened sources. The laboratory pathway, release criteria, compatibility considerations, intended route and follow-up plan are reviewed as part of the complete protocol. They are not treated as interchangeable product labels.
- Umbilical cord UC-MSC
- Wharton’s jelly WJ-MSC
- Placental
- Dental pulp
- Neural
Cell source, dose, route and supporting care are determined only after a physician reviews the diagnosis, medical history, test results and current treatment.
Every patient journey starts with a careful review
The clinical pathway is individual, but the first step is consistent: understand the diagnosis, the evidence and the patient’s priorities before discussing options.
Complex-care programs across multiple specialties
Select a medical specialty to learn more about the conditions we evaluate and treat, their clinical significance, and the level of assessment and treatment information available through our center.
Cancer care depends on the cancer type, stage, biomarkers, previous treatment and the patient's health. Blood-forming stem-cell transplantation, immune-cell treatments, surgery and other oncology procedures serve different purposes. Evidence for a transplant in a selected blood cancer cannot establish benefit from a different cell product in a solid tumor. Review any proposed addition to treatment with the oncology team, including the product, clinical evidence, risks and interaction with standard care.
Heart failure, coronary artery disease and peripheral vascular disease are different clinical problems. Proposed cell-based approaches should be evaluated for the actual diagnosis, preparation, route and measured outcomes. Laboratory cardiomyocyte-like properties or cell-signaling effects do not establish replacement of heart muscle, pacemaker cells or damaged vessels in patients. Continue assessment of medicines, devices and procedures with the treating cardiology team.
COPD, emphysema and pulmonary fibrosis differ in their causes, course and treatment. Cell-based approaches are under investigation; a proposed effect on inflammation does not establish growth of new lung tissue or an alternative to an indicated transplant. Lung-function measurements, symptoms, exacerbations, follow-up and adverse events require intervention-specific assessment. Existing respiratory care and any transplant advice need individual specialist review.
Brain and spinal-cord conditions differ in their causes, affected structures and treatment needs. Neural, mesenchymal and blood-forming cell preparations are different products. Laboratory neural differentiation does not establish restored neurological function in autism, cerebral palsy, stroke, ALS or a spinal injury. Consider the actual diagnosis, preparation, human evidence, rehabilitation needs and procedure-specific risks with the treating specialist.
Integrated regenerative medicine services
Everything your treatment journey needs, in one center.
Cryogenic cell banking
Long-term cryopreservation and storage services.
Radiology & imaging
Diagnostic imaging to guide and monitor care.
Genetic testing & screening
DNA testing and screening to help personalize evaluation.
Cancer immunotherapy
Personalized immunotherapy evaluation and treatment options.
Your stem cell therapy questions, answered
Begin with a confidential review of your diagnosis, current care and medical records. The team will explain what can be assessed remotely, what additional information may be needed and whether a physician consultation is an appropriate next step.
A coordinated first reviewRecords, imaging and goals considered together
What conditions can stem cell therapy treat?
Our team evaluates neurological, orthopedic, cardiovascular, liver, kidney, lung, autoimmune and other degenerative conditions. Suitability depends on an individual medical review.
What happens after I submit my medical records?
The coordination team organizes the available history, imaging and test results for medical review. If more information is needed, you will receive a clear request before a consultation is arranged.
What types of stem cells do you use?
Protocols may involve autologous or allogeneic cell sources. The selected source depends on the condition, medical history, available evidence and physician review.
How is treatment planning personalized?
Recommendations are individualized to the diagnosis, medical history, test results, current care and treatment goals rather than selected from a preset package.
How do I know if I’m a candidate for treatment?
Submit your medical records for a confidential evaluation. The medical team will advise whether further consultation or treatment may be appropriate.
Insights and updates from the Regeneration Center
Evidence-informed articles on regenerative medicine, cellular therapies and patient care.
8 Signs of Early-Stage Liver Disease to Watch For
Early-stage liver disease usually causes no symptoms. Most people with fatty liver disease have no symptoms or only vague ones, and many people with cirrhosis, the stage of heavy scarring, have none early on.[1][2] When researchers tested adults in the…
Read article →Stem Cell Secretome: A Paradigm Shift in Regenerative Medicine
The secretome is the set of molecules and particles a cell releases into the space around it: soluble proteins such as growth factors and cytokines, free nucleic acids, lipids and extracellular vesicles, of which exosomes are one type.[1] In regenerative…
Read article →Muse Cells: Endogenous Pluripotent-Like Stem Cells in Adult Tissues
Muse cells (multilineage-differentiating stress-enduring cells) are a small subpopulation of cells in adult human connective tissues, such as bone marrow, skin and fat, that carry the surface marker SSEA-3 and survive severe stress in culture. They were described in 2010…
Read article →Is Exposure to Incense Worse Than Smoking Cigarettes?
Incense is burned every day in homes and temples across much of Asia and in religious and meditation practice worldwide. Its smoke is an indoor air pollutant, and headlines have compared it with cigarette smoke. The comparison comes mainly from…
Read article →Immunomodulation & the Regulation of the Immune System
Immunomodulation means changing the strength or direction of an immune response. Some treatments strengthen it: vaccines teach the immune system to recognise an infection in advance, and checkpoint inhibitors release the brakes on T cells that attack cancer.[1][2] Others damp…
Read article →Stem Cell Research: The Future with Regenerative Medicine
Stem cell research studies cells that can renew themselves and give rise to specialized cells (in the adult body, stem cells keep this ability throughout life[1]), with two aims: to understand how tissues develop, renew and fail, and to turn…
Read article →Advancing regenerative medicine with compassionate, evidence-informed care
Begin with a confidential review of your diagnosis, medical history and available records.
Request evaluation